The ability of the Cellworks Group's Virtual Skin platform to perform complex experiments with easy setup and to analyze hundreds of bio-molecules and skin attributes gives us unprecedented insight into the workings of biofunctionals we have under development
Saratoga, CA (PRWEB) August 14, 2009
Cellworks Group Inc., a proteomics-driven therapy design company, and ISP Personal Care, a global supplier of advanced personal care ingredients, announced that they have formed an alliance to use sophisticated computer modeling techniques to develop and demonstrate novel skin care approaches based on ISP's Vincience line of biofunctional ingredients. In a recently concluded study, Cellworks Group's Virtual Skin platform was used to model the effects in two biofunctional ingredient projects that were under evaluation for effects on skin pigmentation. The study was able to assay hundreds of bio-molecules, examining different application rates and allowing ISP to predict their effects on different skin types - before the need for expensive clinical testing. Laboratory work by ISP was able to validate the accuracy of the results produced via Cellworks Group's Virtual Skin platform. This study was the first in a series of collaborations between the two companies that will also include work on anti-aging compounds and synergies between different biofunctional ingredients. The alliance is an outgrowth of ISP Personal Care's recently announced Avant Institute for developing scientific and commercial innovation for the personal care industry.
According to Dr. Claude Dal Farra, Vice President of Research & Development for ISP, Cellworks Group's Virtual Cells technology has the potential to dramatically speed up the discovery and development of biofunctional ingredients, to improve the targeting and efficacy of those ingredients, and to deliver important data to skin care companies for use in their own product development processes. "The ability of the Cellworks Group's Virtual Skin platform to perform complex experiments with easy setup and to analyze hundreds of bio-molecules and skin attributes gives us unprecedented insight into the workings of biofunctionals we have under development," he said. "We've been closely working with the Cellworks Group to validate the predictive power of their technology and were very impressed with the accuracy of their system and the ease of interacting with the technology. Working with their virtual skin platform in order to model the interaction of the melanocyte, keratinocyte and fibroblast is a tremendous advantage as the co-culture equivalent would require primary cell lines that only last 48 hours at best, imposing high costs and extreme time pressures. This technology has the ability to improve the productivity of our scientists and enable us to get better products to market in a shorter time," he added.
The next era of skin care study
Proteomics is the large-scale study of proteins, particularly their structures and functions. After genomics, proteomics is often considered the next step in the study of biological systems. It is significantly more complicated than genomics, because, while an organism's genome is more or less constant, the proteome differs from cell to cell and from time to time. This means that even the basic set of proteins that are produced in a cell needs to be determined. Scientists are interested in proteomics because it gives a much better understanding of an organism and a more holistic understanding than genomics alone can provide. Cellworks breakthrough technology merges reductionist proteomics data, clinical trends to produce a platform that is quantitative, dynamic and predictive.
Cellworks Group models the complex protein interactions within various cell types to predict potential human benefits and toxicity of molecules before expensive clinical trials are conducted. The ability to perform complex experiments and assay thousands of markers via computer modeling (in silico) allows dramatic savings in time and cost versus traditional laboratory approaches. Cellworks Group's Virtual Cells platform simulates the interaction of key human cell types and in the case of the studies with ISP, enables predictive analysis of biofunctional compounds on human skin. This Virtual Prototyping allows the analysis of thousands of different scenarios - where traditional laboratory experiments might focus on two or three. The Virtual Skin, which models the dynamic interaction of the multiple key cell types, gives the researcher a holistic understanding of the interaction of a compound with human cells and is highly effective in understanding potential side effects of compounds.
According to Pradeep Fernandes, President of the Cellworks Group, the collaboration between ISP Personal Care and Cellworks Group has demonstrated the potential of proteomics-based approaches in skin care. "Our work with ISP Personal Care in the pigmentation area has been very fruitful and rewarding. These "blinded" validations are a very critical component in quantifying the accuracy of the predictive technology that has been developed. This relationship and the close interactions with the leading scientists at ISP will help us focus our platform centered on aging and allow us to create another innovative system targeting a new and growing market," he said. "This tight collaboration and alliance also opens up opportunities in identifying synergistic therapies in a high throughput fashion as well as new target identification," he added.
International Specialty Products Inc. (ISP) is a leading global supplier of specialty chemicals and performance enhancing products for a wide variety of personal care, pharmaceutical, food, beverage and industrial applications. ISP produces more than 400 specialty chemicals, which it markets and sells worldwide. The company's headquarters is located in Wayne, New Jersey, USA.
About Cellworks Group
Cellworks Group Inc. is a proteomics driven life-sciences company designing therapies using their ground breaking disease platforms in the Skin, Oncology and Inflammation areas. Cellworks Group systems predict efficacy and toxicity pre-clinicals, enable patient stratification and identify dosing regimens, thus dramatically reducing the cost and improving the success rate of therapeutics. More information regarding the use of Cellworks technology in therapy design and Cellworks expertise can be found in http://www.cellworksgroup.com
This press release may contain "forward-looking statements" within the meaning of the federal securities laws and, as such, concerns matters that are not historical facts. These statements are based on our current expectations and assumptions, which are subject to a number of risks and uncertainties that could cause the actual results to differ materially from those anticipated, projected or implied. We undertake no obligations to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
# # #